COVID-19 XWG-03

**COVID-19 XWG-03** is a preclinical recombinant protein subunit vaccine candidate developed by Xiamen Innovax Biotech with Xiamen University for prevention of COVID-19. It was designed around multiple truncated forms of the SARS-CoV-2 spike glycoprotein, which were to be screened for immunogenicity to select a lead antigen. In April 2020, GSK agreed to provide its pandemic adjuvant system for preclinical evaluation, intended to strengthen antigen-specific immune responses and reduce the protein antigen dose required per vaccination. Publicly available reporting does not identify clinical trials or a subsequent clinical-stage program for this candidate. ([genengnews.com](https://www.genengnews.com/news/glaxosmithkline-gsk-xiamen-innovax-biotech-and-xiamen-university/))